tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Finn L et al. | Epstein-Barr virus infections in children after transplantation of the small intestine. | 1998 | Am. J. Surg. Pathol. | pmid:9500771 |
| Randhawa PS et al. | The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. | 1993 | Am. J. Surg. Pathol. | pmid:7680544 |
| Minervini MI et al. | Acute renal allograft rejection with severe tubulitis (Banff 1997 grade IB). | 2000 | Am. J. Surg. Pathol. | pmid:10757402 |
| Randhawa PS et al. | Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. | 1996 | Am. J. Surg. Pathol. | pmid:8772784 |
| Spada M et al. | Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. | 2006 | Am. J. Transplant. | pmid:16771811 |
| Frassetto LA et al. | Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. | 2007 | Am. J. Transplant. | pmid:17949460 |
| Saliba F et al. | Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. | 2017 | Am. J. Transplant. | pmid:28133906 |
| Cosio FG and Larson TS | Cardiovascular disease after transplantation: do we know all of the variables? | 2003 | Am. J. Transplant. | pmid:12859523 |
| Levitsky J and Feng S | Sirolimus and mTOR inhibitors in liver transplantation: the wheel has come full circle. | 2014 | Am. J. Transplant. | pmid:24620373 |
| de Fijter JW et al. | Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. | 2017 | Am. J. Transplant. | pmid:28027625 |
| Krämer BK et al. | Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. | 2003 | Am. J. Transplant. | pmid:12859533 |
| Ciancio G et al. | The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients. | 2003 | Am. J. Transplant. | pmid:12859538 |
| Trofe-Clark J et al. | Immunosuppression, generic drugs and the FDA. | 2012 | Am. J. Transplant. | pmid:22176626 |
| Latran M | Response to Klintmalm on the use of generic immunosuppression. | 2012 | Am. J. Transplant. | pmid:22176636 |
| Asrani SK et al. | De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. | 2014 | Am. J. Transplant. | pmid:24456026 |
| Song L et al. | ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys. | 2017 | Am. J. Transplant. | pmid:27598231 |
| Ekberg H et al. | Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. | 2009 | Am. J. Transplant. | pmid:19563339 |
| Duncan FJ et al. | Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. | 2007 | Am. J. Transplant. | pmid:17941958 |
| Hu X et al. | Chimeric Allografts Induced by Short-Term Treatment With Stem Cell-Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: A Study in Rats. | 2016 | Am. J. Transplant. | pmid:26749344 |
| Cameron AM et al. | Chimeric Allografts Induced by Short-Term Treatment With Stem Cell Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: II, Study in Miniature Swine. | 2016 | Am. J. Transplant. | pmid:26748958 |
| Flechner SM et al. | Allotransplantation of cryopreserved parathyroid tissue for severe hypocalcemia in a renal transplant recipient. | 2010 | Am. J. Transplant. | pmid:20883540 |
| Koefoed-Nielsen PB et al. | Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. | 2002 | Am. J. Transplant. | pmid:12099520 |
| BenÃtez CE et al. | ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. | 2010 | Am. J. Transplant. | pmid:20883560 |
| Madariaga ML et al. | Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma. | 2015 | Am. J. Transplant. | pmid:25824550 |
| Pescovitz MD et al. | A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19663892 |
| Vanrenterghem Y et al. | Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. | 2005 | Am. J. Transplant. | pmid:15636615 |
| Bryan CF et al. | Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. | 2007 | Am. J. Transplant. | pmid:17359511 |
| Vincenti F et al. | Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. | 2007 | Am. J. Transplant. | pmid:17359512 |
| Cendales L et al. | Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report. | 2015 | Am. J. Transplant. | pmid:25773260 |
| Jaksch P et al. | Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. | 2014 | Am. J. Transplant. | pmid:25039364 |
| Neuberger JM et al. | Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. | 2009 | Am. J. Transplant. | pmid:19120077 |
| Tan HP et al. | Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. | 2009 | Am. J. Transplant. | pmid:19120078 |
| Ashman N et al. | Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. | 2009 | Am. J. Transplant. | pmid:19120084 |
| Asrani SK and O'Leary JG | Can one pill a day keep rejection away? | 2015 | Am. J. Transplant. | pmid:25703394 |
| Bhorade SM et al. | Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. | 2003 | Am. J. Transplant. | pmid:14629288 |
| Okabayashi T et al. | Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination. | 2011 | Am. J. Transplant. | pmid:21883903 |
| Hellemons ME et al. | Former smoking is a risk factor for chronic kidney disease after lung transplantation. | 2011 | Am. J. Transplant. | pmid:21883906 |
| Schrepfer S et al. | Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. | 2007 | Am. J. Transplant. | pmid:17532751 |
| Grinyo JM et al. | Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. | 2004 | Am. J. Transplant. | pmid:15268733 |
| Pallet N et al. | Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. | 2015 | Am. J. Transplant. | pmid:25588704 |
| Schussler T et al. | Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. | 2004 | Am. J. Transplant. | pmid:15268744 |
| Teuteberg JJ et al. | Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. | 2010 | Am. J. Transplant. | pmid:19889126 |
| Haufroid V et al. | CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. | 2006 | Am. J. Transplant. | pmid:17049058 |
| Gaston RS et al. | Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. | 2009 | Am. J. Transplant. | pmid:19459794 |
| Lake JR et al. | Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. | 2005 | Am. J. Transplant. | pmid:16303011 |
| Turgut F and Akcay A | Renal function estimation in cirrhosis. | 2009 | Am. J. Transplant. | pmid:19519814 |
| Irish WD et al. | Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. | 2011 | Am. J. Transplant. | pmid:21564522 |
| Friman S et al. | Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. | 2011 | Am. J. Transplant. | pmid:21564523 |
| Margreiter R et al. | Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. | 2008 | Am. J. Transplant. | pmid:18510632 |
| Mandelbrot DA et al. | Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus. | 2015 | Am. J. Transplant. | pmid:26176342 |